Karin Yoo is an associate in the firm’s Business Law department and a member of its nationally recognized Life Sciences group. Karin represents clients across the biotechnology, pharmaceutical and life sciences industries, including public and private companies and investment banks, throughout the full range of the corporate life cycle, and has worked with many of her issuer-side clients since their initial founding and funding.
Karin advises public and private companies on startup and formation matters, venture capital financings, strategic investments and capital markets transactions, including initial public offerings, follow-on public offerings, ATMs and PIPEs, as well as other complex transactions. She also represents publicly traded biotechnology companies in ongoing corporate matters, including SEC and securities law compliance and corporate governance matters. She joined Goodwin in 2018.
Representative Matters
- Aclarion in its $4.7 million registered direct offering
- ProQR Therapeutics in its $103.5 million follow-on offering, its convertible debt financing, and its $63 million follow-on offering and concurrent $12 million private placement
- Septerna in its $288 million upsized initial public offering
- Prime Medicine in its $300 million at-the-market offering, $161 million follow-on offering, and its $3.5 billion global collaboration and $55 million equity investment with Bristol-Myers Squibb
- The underwriters in PACS Group’s $517 million upsized initial public offering and $690 million upsized primary and secondary follow-on offering
- The placement agent in Acrivon Therapeutic’s $130 million PIPE financing
- Esperion Therapeutics in its $97.8 million follow-on offering
- Entrada Therapeutics in its $181.5 million upsized initial public offering and its $100 million registered direct offering
- Brainstorm Cell Therapeutics in its $7.5 million registered direct offering
- Relay Therapeutics in its $300 million follow-on offering
- Black Diamond Therapeutics in its $231.3 million initial public offering and its $150 million at-the-market offering
- Cerevel Therapeutics in its $250 million at-the-market offering, its $350 million follow-on offering, and its $573 million concurrent equity and convertible notes offerings
- Aerpio Therapeutics in its reverse merger with Aadi Biosciences and its concurrent $155 million PIPE financing
- Achilles Therapeutics in its $175.5 million initial public offering
- Bicycle Therapeutics in its $60 million initial public offering
- Nimbus Therapeutics in its multiple financings of more than $375 million
- ROME Therapeutics in its formation, its $50 million Series A financing, and its $149 million Series B financing
- Entrada Therapeutics in its $25 million Series A financing extension and its $116 million Series B financing
- Aura Biosciences in its $20 million Series D financing and its $80 million Series E financing
- DROIA, RA Capital and Mission Bay Capital in their investments in the $18 million Series Seed financing for AmbAgon Therapeutics
- Black Diamond Therapeutics in its $85 million Series C financing
- Charles River Ventures in its investment in the $2.9 million Series Seed-1 financing for Zoba
Professional Activities
While in law school, Karin served as a staff editor of the Boston College Law & Religion Review and the Boston College Intellectual Property and Technology Forum. She was a summer associate at a prominent employment litigation law firm in Boston. In 2017, Karin worked as an honors legal intern in the Asset Management Unit of the Enforcement Division at the U.S. Securities and Exchange Commission in New York.
Karin is a member of the Boston and American Bar Associations.
Credentials
Education
JD2018
Boston College Law School
BASociology2011
New York University
Admissions
Bars
- Massachusetts
Recognition & Awards
Karin was a Public Interest Designation Fellow and was a recipient of a Pro Bono Excellence Award at Boston College Law School.